Table 2.

Summary of blood glucose control results (per-protocol population)

Parameter	CSII	MDI	Difference at end point (95% CI)
A1C (%)
Baseline	7.7 ± 0.7	7.8 ± 0.6
End point	7.0 ± 0.8	7.2 ± 0.7	−0.1 (−0.5 to 0.3)
SMBG [mmol/l (mg/dl)]
Fasting
Baseline	10.1 ± 3.3 (183 ± 60)	10.4 ± 3.2 (188 ± 57)
End point	6.8 ± 1.7 (123 ± 30)	7.7 ± 2.4 (139 ± 43)	−0.7 (−1.8 to 0.5)
Preprandial
Baseline	7.8 ± 3.6 (140 ± 64)	8.0 ± 3.0 (145 ± 53)
End point	6.7 ± 2.4 (120 ± 43)	7.7 ± 2.4 (138 ± 42)	−0.9 (−2.3 to 0.4)
Postprandial
Baseline	8.4 ± 3.6 (151 ± 66)	6.9 ± 2.6 (125 ± 47)
End point	8.2 ± 2.3 (147 ± 42)	7.6 ± 2.1 (136 ± 39)	0.3 (−1.1 to 1.7)
0300 h blood glucose [mmol/l (mg/dl)]
Baseline	8.4 ± 4.8 (151 ± 87)	7.8 ± 5.0 (141 ± 90)
End point	8.8 ± 2.3 (158 ± 42)	8.1 ± 4.3 (146 ± 78)	3.0 (−0.4 to 6.5)
Blood glucose [mmol/l (mg/dl)]
Baseline	9.1 ± 2.3 (164 ± 41)	8.9 ± 1.6 (160 ± 30)
End point	8.1 ± 1.8 (146 ± 32)	8.0 ± 1.1 (144 ± 20)	0.03 (−0.7 to 0.8)
MAGE [mmol/l (mg/dl)]
Baseline	8.0 ± 2.4 (144 ± 43)	7.6 ± 1.7 (137 ± 31)
End point	6.4 ± 2.2 (115 ± 40)	6.4 ± 2.1 (115 ± 38)	−0.4 (−1.8 to 1.0)

Data are means ± SD unless otherwise indicated. The per-protocol population consisted of patients who were correctly randomized and receiving study insulin. MAGE, mean amplitude of glycemic excursion; SMBG, self-monitored blood glucose.